Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib

Conclusions: Predictions of overall survival and post ‐progression survival were possible by periodically measuring serum proangiogenic cytokines, especially angiopoietin‐2, in patients with HCC treated with sorafenib.

Source: Journal of Gastroenterology and Hepatology - November 6, 2018 Category: Gastroenterology Authors: Takuya Adachi, Kazuhiro Nouso, Koji Miyahara, Atsushi Oyama, Nozomu Wada, Chihiro Dohi, Yasuto Takeuchi, Tetsuya Yasunaka, Hideki Onishi, Fusao Ikeda, Shinichiro Nakamura, Hidenori Shiraha, Akinobu Takaki, Hiroyuki Takabatake, Shin ‐ichi F Tags: Hepatology Source Type: research